Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381861 · ClinicalTrials.gov registry record · Phase 2
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 study of Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 7
- Study locations
NCT01381861 is a Phase 2 study of Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 23 participants, below the 330-participant average among 20 other Primary Peritoneal Carcinoma trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT01381861, a Phase 2 study of Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Conditions Studied
Interventions
- BIOLOGICAL Carotuximab (TRC105)
Study Locations (7)
California
- University of California, San Diego - La Jolla
- University of Southern California - Los Angeles
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Palm Beach Cancer Institute - West Palm Beach
Indiana
- Indiana University-Bren and Melvin Simon Cancer Center - Indianapolis
New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01381861
The ClinicalTrials.gov registry entry for NCT01381861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 330-participant average among 20 other Primary Peritoneal Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Peritoneal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Carotuximab (TRC105) is the first listed.
NCT01381861 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT01381861 about?
NCT01381861 is a clinical study titled "Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma". The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
What is the current status of trial NCT01381861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-07. Estimated completion is 2013-12.
What conditions does trial NCT01381861 study?
This clinical trial studies the following conditions: Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent Ovarian Cancer.
What interventions are being tested in trial NCT01381861?
The interventions under investigation include: Carotuximab (TRC105) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01381861?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01381861 being conducted?
This trial has 7 study locations across Alabama, California, Florida, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Peritoneal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.